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GH deficiency (GHD) is associated with a higher risk of vas-
cular disease,whosepathophysiologicalmechanisms remains
not yet fully elucidated. This study aimed to assess the main
cardiovascular risk indexes, plasma catecholamines content,
and the platelet function in childhood-onset GHD patients.
Some of the main clinical examinations related with car-
diovascular risk, plasma catecholamines content, as well as
platelet intracellular free calcium concentration ([Ca2]i),
whole-blood aggregation, and morphology were evaluated in
childhood-onset GHD patients treated with GH for a variable
period and off GH therapy for at least 2 yr before entry into
study and in sex-, age-, and body mass index-matched control
groups. Among the patients, group 1 (GHD-1) has recovered
GH levels after withdrawal, whereas group 2 (GHD-2) has
remained GH deficient.
Minor differences on the cardiovascular risk indexes were
observed between the groups. Plasma catecholamine concen-
trations in theGHDgroups didnot statistically differ from the
control group, but higher adrenaline content was observed in
the GHD-2 group when compared with the GHD-1 one. Basal
and thrombin-evoked [Ca2]i and platelet aggregation were
identical between the GHD-1 group and the matched control.
However, the GHD-2 group has increased thrombin-evoked
[Ca2]i (297.0  15.7 nmol/liter; P < 0.01), collagen, and ADP-
induced platelet aggregation (33.3  4.3 and 12.5  2.1 , re-
spectively; P < 0.05) vs. the control-2 group ([Ca2]i: 102.1 
13.6 nmol/liter; aggregation: 19.6  2.9 and 6.2  0.8 ). The
platelet hyperreactivity state in the GHD-2 was reinforced by
morphologic studies of electron microscopy.
In conclusion, there were minor differences between the
GHD-1 group and the controls, which might be due to the
recovery of GH levels after therapy withdrawal. However,
the maintained GHD group, despite minor cardiovascular
risk index differences, has increased [Ca2]i and aggrega-
tion, which could indicate a hyperactivation state that
might be viewed as an earlier marker of cardiovascular
disturbances. (J Clin Endocrinol Metab 90: 98–105, 2005)
GH DEFICIENCY (GHD) SINCE the developmental pe-riod may predict a higher risk for cardiovascular dis-
ease, which includes abdominal adiposity, dyslipoproteine-
mia and dyslipidemia, decreased fibrinolytic activity, insulin
resistance, glucose intolerance, and increased prevalence of
hypertension (1–5). Adults with hypopituitarism have twice
the cardiocerebrovascular mortality rate of the normal pop-
ulation as well as reduced longevity, which seems to be due
to untreated GHD (1, 3, 5, 6). The mechanisms underlying
this condition remain poorly understood. However, several
biochemical vascular abnormalities have been described in
GH-deficient young adults who do not have the classic car-
diovascular risk factors (diabetes, obesity, dyslipidemia, and
hypertension) including increased peripheral resistance, re-
duction of aortic distensibility, and increased sympathetic
nerve activity (7–9). Moreover, a significant increase in
intima-media thickness, higher number of atheromatous
plaques, and endothelial dysfunction have been reported in
hypopituitary adults, despite adequate hormonal therapy
except for GH, which support the causal role for GHD in
determining premature atherosclerosis (10–13). Replace-
ment therapywithGHhas demonstrated favorable effects on
some of the above-mentioned cardiovascular risk factors (2,
3, 14). However, this issue is not consensual in view of the
fact that some studies did not confirm cardiovascular dys-
function in GH-deficient hypopituitary adults, whereas
others reported no benefits for some of the disturbances
associated with GHD (15–18). Most of the studies in the
literature were based on clinical examination data, and few
works are available concerning the cellular and molecular
mechanisms underlying the pathophysiology of GHD-in-
duced increased risk of vascular disease. So GH replacement
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therapy after completion of growth to prevent increased
cardiovascular risk in the adult age remains controversial,
and the clinical decision to do so is not wholly supported by
scientific studies; thus, it is not licensed in several countries.
The diagnosis ofGHDalwayswas difficult to establish and
remains controversial for several reasons: the onset of the
disorder (childhood or adulthood-onset deficiency), the def-
inition of the transition period or the need of therapy con-
tinuation after growth completion (19–21), the tests used for
the GHD assessment (22), the causes of their hypopituitar-
ism/etiology of the GHD (idiopathic or congenital/muta-
genic) (23, 24), the nature of the hypopituitarism (isolated,
combined, or multiple hormone deficiency) as well as the
GHD persistence and severity in the adulthood (19–21, 25).
Almost all the data available are derived from adult GHD,
but it cannot be excluded that some metabolic and/or vas-
cular abnormalities were already present when hypopitu-
itarism set in. So if well defined and characterized, themodel
of childhood-onset GH-deficient (COGHD) patients might
be particularly useful (19, 25, 26) and has been increasingly
used to investigate GHD.
Platelets are mediators of thromboembolic complications
and promoters of arteriosclerosis (27, 28). In addition, plate-
lets produce, store, and/or release some vasoconstriction
agents (such as serotonin and thromboxane A2), which may
affect both endothelium and vascular smooth muscle cell
(VSMC) activity and influence vasoconstriction and periph-
eral vascular resistance. These corollaries, as well as their
easy clinical accessibility and the features they have in com-
mon with VSMCs (29), make them useful tools in the study
of pathophysiological abnormalities related with the vascu-
lature, namely the widespread alterations in membrane and
intracellular mechanisms underlying vascular disease devel-
opment. Intracellular calcium is an essential second messen-
ger in platelet responses and is the major determinant of
vascular smooth muscle contractile activity (30, 31). Conse-
quently, an increase in cytosolic Ca2 in arterial smooth
muscle leads to an increase in peripheral resistance that
might contribute to vascular dysfunction. Therefore, an un-
derstanding of the general principles of cellular Ca2 regu-
lation in GHD patients might be crucial to find the main
mechanisms underlying GHD-increased cardiovascular
risks.
The purpose of this study was to assess some of the main
cardiovascular risk indexes and plasma catecholamines lev-
els and compare someplatelet activation parameters (namely
intracellular free calcium content, whole-blood platelet ag-
gregation, and morphology) in two groups of COGHD pa-
tients (one with maintained GHD and the other with recov-
ered GHD after withdrawal) treated with GH therapy for a
variable period and in sex-, age-, and bodymass index (BMI)-
matched control groups.
Subjects and Methods
Subject selection and characterization
Four groupswere tested: two groups ofCOGHDpatients treatedwith
GH therapy for a variable period until growth completion, and a sex-,
age ( 2), and BMI ( 2)-matched control group of healthy volunteers
for each GHD group of patients to avoid body weight interferences
(Table 1). GHD had been diagnosed in their childhood by means of
auxological data (stature, growth rate, and bone age) and biochemical
tests (19). At least two stimulation tests were performed: clonidine and
insulin-induced hypoglycemia (22). GH response after stimulation tests
less than 7 ng/ml and IGF-I below the normal range for age and sexwere
determinant for their diagnosis. GH therapy had been administered at
the dose of 0.5–0.7 UI/kgwk in all patients for a period ranging from
3 to 8 yr and was withdrawn at least 2 yr before entry into the study.
The criteria for therapy withdrawal were well-defined auxologic mea-
sures (growth rate and bone age) (19, 32). Patients from both GHD
groups were stabilized on conventional hormone replacement therapy
(HRT), when appropriate, with T4, testosterone, estrogen/progestin,
cortisone, and desmopressin. Each treatment corresponds to the dose
needed for each particular subject and at each time point to repose the
normal values for age and sex. All the HRTs were stopped for at least
2 yr before entry into the study and were at the normal levels.
The children were reevaluated 6 months to 6 yr after therapy with-
drawal. The same stimulation tests, clonidine and insulin-induced hy-
poglycemia, were performed in these patients, and we did consider that
the GHD was present when the peak level of GH was less than 3 ng/ml
(33). Among the GHD subjects, some patients recovered GH levels after
therapy withdrawal (group GHD-1: n  10), whereas others remained
GH deficient when retested for GH (group GHD-2: n  8) after therapy
was already withdrawn. There were several causes of hypopituitarism/
etiology of the GHD in the two groups of COGHD patients. From the
eight patients in theGHD-2 group (whichmaintained severeGHDwhen
retested; peak GH level  3 ng/ml), two had craniopharyngioma, one
had Rathke’s cleft cyst, one had optic nerve gioma, two had empty sella
syndrome, one had pituitary hypoplasia, and one had idiopathic GHD.
From the 10 patients in the GHD-1 group (with normal GH levels when
retested for GH; 7 ng/ml), two had operated craniopharyngioma, two
had pituitary hypoplasia, and six had idiopathic GHD. One patient had
panhypopituitarism with all anterior pituitary hormones and anti-
diuretic hormone deficiency (five-axis deficiency); two patients had a
combination of GH, gonadal, adrenal, and thyroid axis deficiency (four-
axis deficiency); two patients had a combination of GH, thyroid, and
gonadal axis deficiency (three-axis deficiency); seven patients had a
combination of GH and thyroid or GH and gonadal axis deficiency
(two-axis deficiency); and six had isolated GHD. Two patients were
submitted to radiotherapy. Control subjects (n  7 for each control
group) were recruited from students at the Institute of Pharmacology
and Experimental Therapeutics, Medicine Faculty, Coimbra University.
The study was performed according to the principles established in the
Helsinki Declaration and was ethically approved by the Portuguese
TABLE 1. General characterization of the GHD groups and the sex-, age-, and BMI-matched control groups: anthropometric and blood
pressure data
Parameters Control-1 group(n  7)
GHD-1 group
(n  10)
Control-2 group
(n  7)
GHD-2 group
(n  8)
Sex (male/female) 4/3 6/4 4/3 5/3
Age (yr) 22.3  0.8 22.0  1.0 24.9  0.3 26.6  1.7
BMI (kg/m2) 26.3  0.5 24.4  1.7 24.6  1.1 22.9  1.7
WHR ratio 0.9  0.1 0.9  0.1 0.9  0.1 0.9  0.1
SBP (mm Hg) 111.3  5.1 110.6  2.7 113.7  4.1 114.0  5.1
DBP (mm Hg) 69.0  7.0 67.8  4.6 67.3  5.9 70.7  5.8
Data are expressed as means  SEM of n individuals. GHD-1; GHD group 1; GHD-2; GHD group 2; WHR ratio, waist to hip ratio.
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Ethics authorities. All the subjects, patients, and control healthy volun-
teers were informed and gave their written consent.
There were no hypertension, diabetes mellitus, or smoking habits in
the four groups. No differences were observed in anthropometric eval-
uation or fat distribution. Body weight was measured in the morning,
after the subjects had voided, to the nearest 0.1 kg. Body height was
measured barefoot and to the nearest 0.5 cm. No differences were ob-
served in BMI and waist to hip ratio in the four groups (Table 1).
However, BMI values in the control groups were higher than the
matched GHD patients groups, which might be recognized as a non-
typical result that, in further studies, should be taken into consideration.
The systolic and diastolic blood pressure (SBP and DBP) values were the
mean of two measures on the right arm in a random zero sphygmo-
manometer with a cuff size corresponding to the size of the right arm.
Nodifferenceswere observed in the SBP andDBP values among the four
groups (Table 1).
Blood collection and platelet preparation
Blood were collected from the control and GHD patients using ap-
propriate tubes containing anticoagulant solution (0.1 ml/ml blood)
containing (in millimoles per liter) citric acid (71), sodium citrate (85),
and d-glucose (111). The blood was centrifuged (900 rpm for 10 min at
20 C) to obtain platelet-rich plasma, and the platelets were then recov-
ered by a new centrifugation at 2500 rpm for 10 min at 20 C to be used
in the other experimental protocols.
Clinical hematological and biochemical examinations
After one night fasting, blood samples were drawn to appropriated
tubes provided with anticoagulant solution for the determination of
hematological and biochemical parameters. Several laboratory exami-
nations related with hemostase, coagulation, lipids, and apoproteins
were made in each of the four groups, using standard laboratory tech-
niques. It included platelet count, prothrombin time, partial thrombo-
plastin time (PTT), fibrinogen, hemoglobin, total cholesterol (T-Chol),
low-density lipoprotein cholesterol (LDL-Chol), high-density lipopro-
tein cholesterol (HDL-Chol), triglyceride (TG), apoprotein (apo) A1 and
B, apo B to apo A1 ratio, pre-- and -electrophoretic bands of
lipoproteins.
Plasma catecholamine concentration
Plasma catecholamines were measured as previously described (34).
In brief, to 2 ml plasma, obtained as mentioned above, 100 ng/ml of the
internal standard 3,4-dihydroxybenzylamine, 50 mg alumina, and 1 ml
Tris buffer [1 mol/liter (pH 8.6)] were added. The catecholamines in the
samples, extracted by using the method of alumina adsorption and
appropriate microfilter systems, were finally resuspended in perchloric
acid (100 mmol/liter) to be further quantified by HPLC with electro-
chemical detection, using the chromatographic conditions already
described (34). Noradrenaline, adrenaline, and dopamine concentra-
tions (in picograms per milliliter) were calculated by using the authentic
standards of each one and the internal standard of 3,4-dihydroxyben-
zylamine (Sigma Chemicals, St. Louis, MO), intended to correct the
possible catecholamine loss during the alumina extraction procedure.
HPLC catecholamine recovery was greater than 95%, and within-assay
and between-assay variability coefficients for the noradrenaline, adren-
aline, and dopamine quantification were less than 2 and less than 4%,
respectively.
Platelet intracellular free calcium concentration ([Ca2]i)
The preparation of fura-2-loaded platelets was made as previously
described (35). In brief, the platelet pellet, obtained as above described,
containing 100 mol/liter of acetyl-salicylic acid was resuspended and
incubated for 10 min in a physiological saline solution containing 20
g/ml apyrase and loaded with 5 mol/liter fura-2/AM (Molecular
Probes Inc., Eugene, OR) for 45 min at 37 C. The fluorescence of the
platelet suspension finally obtained (2500 rpm, 10 min, 20 C) was mea-
sured at 37 C with continual agitation at the emission wavelength of 510
nm, with the excitation wavelength continuously switched between 340
and 380 nm (FluoroMax spectrofluorometer, SPEX Industries Inc., Edi-
son, NJ), using the ratio of the fluorescence intensities to determine
[Ca2]i, according to the equation: [Ca
2]i  Kd [(R  Rmin)/(Rmax 
R)]  (36). [Ca2]i calibration was achieved by lysing the cells with 50
mol/liter digitonin in the presence of 1 mmol/liter CaCl2 or 10 mmol/
liter EGTA (pH 9.0). [Ca2]i was tested at basal conditions and after
addition of 0.1 U/ml thrombin (bovine, lyophilized, DiaMed AG,
Cressier, Switzerland).
Whole-blood platelet aggregation
Whole-blood platelet aggregation was measured by assessing the
electric impedance (37), using a Chrono-log aggregometer (Chrono Log
Corp., Havertown, PA). This technique is based on the detection of
changes in electrical resistance between two electrodes submerged in the
sample. Then 0.5 ml of fresh heparinizedwhole blood and 0.5 ml of 0.9%
NaCl were mixed using a magnetic stirrer and allowed to balance at 37
C for 5min before adding the agonists (collagen-equine type I: 10g/ml;
ADP: 1 mol/liter; Chrono Log Corp.).
Electron microscopy study of platelet activation
The platelet samples from the blood of each of the four groups were
prepared according to the protocol previously described (35). In brief,
the platelet pellets, collected as described above, were fixed with glu-
taraldehyde, washed, and postfixed with osmium tetroxide. After a
further washing, the platelets were then preembedded in agar, which
was cut into 1-mmpieces, dehydratedwith alcohol and propylene oxide,
and finally embedded in a low-viscosity resin Epon 812 (TAAB, Alder-
maston, UK). After polymerization, the blocks were cut on an ultrami-
crotome (LKB) using a diamond knife. Ultrathin sectionswere picked up
on uncoated copper grids (300 mesh) and observed under a JEM-100SX
(JEOL) transmission electronmicroscope, after uranyl/lead citrate stain-
ing. Ten samples of the 14 control individuals as well as all the samples
of both GHD groups (10 of the GHD-1 and eight of the GHD-2) were
analyzed. From each individual sample, a grid was prepared corre-
sponding to 10 different cuts of the biological material to confirm that
the pattern obtained in the picture was not due to the local of the cut.
The quantification was made by calculating the percentage of each
particular pattern (sign) observed in the 300-mesh grid.
Statistical analysis
Results are expressed asmeans sem of n individuals for each group
(as indicated). Groups were tested for differences by performing the
ANOVAandFisher’s least protected significant difference test, using the
Statview 4.53 software (Abacus Concepts Inc., Berkeley, CA). Differ-
ences were considered statistically significant at P 0.05 (*, P 0.05 and
**, P  0.01 vs. the matched control group and #, P  0.05 and ##, P 
0.01 between GHD-2 and GHD-1 groups).
Results
Clinical hematological and biochemical examinations
Concerning the hemostasis and coagulation parameters,
the GHD-1 group significantly differed only in hemoglobin:
a lower value was obtained when compared with the
matched control-1 group. In opposition, in the group that
remained GH deficient after therapy withdrawal (GHD-2
group), therewas a significant higher value of PTT and lower
values of fibrinogen and hemoglobin than the matched
control-2 group (Table 2). In relation to lipid profile and
apoproteins, both GHD groups showed higher TG content
and lower apoAvalue than the corresponding control group.
The HDL-Chol was also numerically lower in both groups
than the matched controls but without reaching statistical
significance, whereas the LDL-Chol values were unchanged.
In the group that remained GH deficient (GHD-2), there was
also a higher T-Chol content when compared with the group
that recovered the GH levels (GHD-1) (Table 2).
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Plasma catecholamine concentration
Plasma noradrenaline concentration differences between
the GHD groups and the matched control group did not
reach statistical significance (Table 3). Plasma adrenaline
content was especially higher in the GHD-2 group, being
significant when compared with the GHD-1 group value.
Plasma dopamine concentration also did not statistically dif-
fer between the GHD and the control groups (Table 3).
Platelet [Ca2]i
Basal [Ca2]i was identical in the four groups (control-1:
86.4  2.2 nmol/liter; GHD-1: 91.0  1.8 nmol/liter; con-
trol-2: 81.7 1.6 nmol/liter; GHD-2 group: 80.2 1.7 nmol/
liter) (Fig. 1). Thrombin-evoked [Ca2]i value was 95.7 
11.5 nmol/liter in the control-1 group and 80.0  4.5
nmol/liter in the GHD-1 group. However, in the GHD-2
group, there was a statistically significant increased throm-
bin-evoked [Ca2]i (297.0  15.7 nmol/liter; P  0.01),
compared with both the matched control-2 (102.1  13.6
nmol/liter) and GHD-1 group (Fig. 1).
Whole-blood platelet aggregation
Collagen-induced whole-blood platelet aggregation val-
ues were similar between the control-1 and GHD-1 groups
(control-1: 26.4  1.5 	; GHD-1: 28.0  2.0 	) (Fig. 2A).
However, the GHD-2 group had a higher collagen-induced
platelet aggregation (33.3 4.3	; P 0.05) when compared
with the matched control-2 group (19.6  2.9 	; P  0.01).
ADP-induced whole-blood platelet aggregation values were
similar between the control-1 (9.2  1.9 	) and GHD-1
groups (6.4 2.0	). However, the GHD-2 group (12.5 2.1
	) showed a statistically significantly (P 0.05) higher value
when compared with the matched control-2 group (6.2 0.8
	) and GHD-1 group (Fig. 2B).
Electron microscopy study of platelet activation
The platelets of the GHD-1 patients showed identical mor-
phological features to those of the control groups (Fig. 3, A1
vs. B1). In Fig. 3, C1 and C2, we observed signs of platelet
activation for the platelets of the GHD-2 group, namely the
pseudopodia formation, contrasting with the regular and
well-defined shape of the platelets from the control volun-
teers (Fig. 3A1) and the GHD-1 patients (Fig. 3B1). In addi-
tion, extensive platelet aggregation was observed for the
platelets of the GHD-2 group, which is evident when both
their spatial distribution (how close to one another) and
complementary shapes (Fig. 3C3) were compared with the
platelets of the control (Fig. 3A1) and GHD-1 groups (Fig.
3B2). These results confirmed the significant increases in
platelet aggregation obtained for the GHD-2 group when
compared with the matched control-2 and GHD-1 groups,
confirming the whole-blood platelet aggregation results
described above.
TABLE 2. Clinical hematological and biochemical examinations in the GHD patients (GHD-1 and GHD-2) and in the matched
control volunteers
Parameters Control-1 group(n  7)
GHD-1 group
(n  10)
Control-2 group
(n  7)
GHD-2 group
(n  8)
Hemostasis and coagulation
PTC (1012/liter) 233  22 234  14 237  30 242  17
PT (sec) 12.5  0.3 13.5  0.3 12.5  0.4 13.2  0.5
PTT (sec) 27.0  1.4 30.7  1.1 25.4  1.9 30.7  2.1a
Fibrinogen (g/liter) 2.2  0.2 2.6  0.1 2.0  0.2 2.9  0.3b
Hemoglobin (mmol/liter) 10.2  0.7 8.4  0.3a 11.0  0.7 8.4  0.3b
Lipid profile
T-Chol (mmol/liter) 5.1  0.2 4.6  0.2 5.1  0.1 5.3  0.3c
LDL-Chol (mmol/liter) 2.4  0.2 2.6  0.2 2.3  0.2 2.4  0.3
HDL-Chol (mmol/liter) 1.3  0.1 1.1  0.1 1.3  0.1 1.2  0.1
TGs (mmol/liter) 0.61  0.05 1.34  0.24c 0.55  0.3 1.14  0.15b
Apoproteins
Apo A (mg/dl) 159  8 131  4a 174  11 139  6a
Apo B (mg/dl) 103  3 90  8 95  5 98  9
Apo B/apo A ratio 0.66  0.03 0.70  0.08 0.56  0.05 0.70  0.06
Alpha (%) 32.2  2.8 35.2  4.4 28.1  2.2 29.0  1.9
Pre-Beta (%) 24.3  3.2 18.5  3.2 26.8  2.9 20.3  3.1
Beta (%) 44.2  1.6 44.1  2.9 44.1  2.1 49.9  2.4
Data are expressed as means SEM of n individuals (a P 0.05 and b P 0.01 vs. the matched control group, and c P 0.05 between GHD-2
and GHD-1 groups). PTC, Platelet count; PT, prothrombin time; GHD-1; GHD group 1; GHD-2; GHD group 2.
TABLE 3. Plasma noradrenaline, adrenaline, and dopamine content in the GHD patients (GHD-1 and GHD-2) and in the matched
control volunteers
Catecholamine
(pg/ml)
Control-1 group
(n  7)
GHD-1 group
(n  10)
Control-2 group
(n  7)
GHD-2 group
(n  8)
Noradrenaline 93  8 123  34 69  16 91  6
Adrenaline 516  138 549  64 526  108 731  98a
Dopamine 79  45 118  42 96  51 118  16
Data are expressed as means  SEM of n individuals (a P  0.05 between GHD-2 and GHD-1 groups). GHD-1, GHD group 1; GHD-2; GHD
group 2.
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Discussion
GH replacement therapy after growth completion to pre-
vent increased cardiovascular risk in the adult age remains
controversial, not only because of the high costs of these
therapy but also, and especially, because of the lack of sci-
entific studies undoubtedly proving the benefits of therapy
prolongation after completion of growth. Benefits of GH
replacement therapy on the cardiovascular indexes, such as
those previously reported by other authors (38), who dem-
onstrated intima-media thickness normalization and early
atherosclerotic disturbances reversion, were not obtained by
all the authors, as could be demonstrated by the noncon-
sensual results (15–18). So whether GH replacement therapy
will restore cardiovascular mortality rates to normal remains
to be undoubtedly shown.
In our study, the lipid profile evaluation demonstrated
that the GHD groups already had significant higher TG con-
tents and lower apo A values when compared with the
matched control groups, even though the age of patients was
still young. All the other parameters analyzed did not sig-
nificantly differ among the groups.However, even not reach-
ing significance, the values for HDL-Chol in both GHD
groups, comparedwith the controls, as well as the significant
higher T-Chol in the GHD-2 group, compared with the
groups that recovered GH levels after therapy (GHD-1),
should be emphasized. GHDwas previously associatedwith
abnormalities of lipid and carbohydrate metabolism, thus
contributing to the increased risk of vascular disease (3, 5).
Elevations of T-Chol and LDL-Chol have been described in
adult GHD patients (39, 40). Our study, in contrast, demon-
strates no differences in T-Chol, LDL-Chol, and apo B apo-
protein in both GHD groups when compared with the con-
trol volunteers. Once the subjects entering the study were
retested COGHD patients off GH replacement therapy, the
nonstatistically significant results could be due to their still
young age at study. Therefore,most, but not all, of the studies
clearly describing changes in those indexes were obtained
from GHD patients already in the adulthood (3, 26, 39, 40).
A study performed by Gleeson et al. (41), assessing the
lipid profile of GHD patients through the life span, reported
an increased T-Chol and LDL-Chol, particularly patents in
adulthood but less marked in child and adolescent GHD
patients, which is not in opposition with our data. However,
the absence of differences on both the TG and HDL-Chol
values in children and also adult GHD patients seems to
withdraw an age or GHD duration influence on these pa-
rameters. Another study also denied a pubertal or GH status
influence in T-Chol, LDL-Chol, and TG abnormalities in
healthy adults (42). In our study, even other lipid profile
parameters, such as the decreased HDL-Chol contents, did
not reach statistical significance, it was demonstrated a
FIG. 2. Whole-blood platelet aggregation in control and GHD pa-
tients (GHD-1 and GHD-2) and the matched control volunteers: in-
duced by 10 g/ml collagen (A) and 1 mol/liter ADP (B). Each bar
indicates the mean  SEM of seven controls in each group, 10 GHD-1
and eight GHD-2 individuals (*, P  0.05 vs. the matched control
group and #, P  0.05 between GHD-2 and GHD-1 groups).
FIG. 1. Basal and thrombin-evoked
platelet [Ca2]i in the GHD patients
(GHD-1 and GHD-2) and the matched
control volunteers. Platelets were incu-
bated with fura-2/AM (5 mol/liter) for
45 min and further stimulated with
thrombin (0.1 U/ml) in the presence of 1
mmol/liter CaCl2 to restore the external
[Ca2] (values obtained are the peak
[Ca2]i, achieved 1 min after the addi-
tion of the agonist). Each bar indicates
the mean  SEM of seven controls in
each group, 10 GHD-1 patients, and
eight GHD-2 individuals, each with two
parallel determinations (**,P 0.01 vs.
the matched control group and ##, P 
0.01 between GHD-2 and GHD-1
groups).
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higher TG concentration and a lower apo A apoprotein level
in the GHD patients, compared with the controls, which
would favor the increased cardiovascular risk and predis-
position for premature atherosclerosis, previously suggested
by others in childhood and adolescent GHD patients (11, 43).
Another possible explanation for the differences, compared
with other studies, is that our patients were under therapy
until growth completion and were off GH treatment when
assessed for the study. Therefore, some of the studies in the
literature were related to untreated GHD patients; further-
more, improvement of lipid metabolism abnormalities in
GHD patients after GH replacement therapy was seen in
several studies (3, 5, 41, 44). So considering the above-
mentioned information, further studies comparing child-
hood GH-deficient patients before GH replacement therapy
and after therapy withdrawal and adulthood GHD individ-
uals might evaluate these influences and confirm or deny the
tendencies of our results and the influence of the above-
described factors.
Concerning the hemostasis and coagulation evaluation, our
study demonstrated a significant difference on only one pa-
rameter analyzed in the GHD-1 group (a lower hemoglobin
value), whereas in the maintained GH-deficient group (GHD-
2), there was clear differences on the PTT and fibrinogen and
hemoglobin values, comparedwith thematched control group.
Other studies have already described GH-associated abnor-
malities in some of the main hemostatic, fibrinolytic, and in-
flammatory markers, such as hyperfibrinogenemia and in-
creased PCR in GHD patients as well as increased hemoglobin
levels in long-term replacement therapy with recombinant hu-
man GH (18, 45–47). The hemostasis and coagulation values
obtained in our study also obligates a further evaluation in
FIG. 3. Electron microscopy photo-
graphs of platelet morphology in the
GHD patients (GHD-1 and GHD-2) and
matched control volunteers (original
magnification, 16,800, except B1,
33,600). A1, Platelets from the control
groups (1 and 2); B1 and B2, Platelets
from the GHD-1 group; C1–C3, Plate-
lets from the GHD-2 group. In the con-
trol groups, 10 samples (individuals) of
the 14 controls were analyzed: in nine of
them, the pattern in A1 was seen in
more than 95% of the grid holes, dem-
onstrating the other one only little ev-
idence of activation in less than 40% of
the grid holes. In the GHD-1 group, the
normal morphology (B1) was observed
in all the samples in more than 85% of
the holes, except two of them that have
shown signs of membrane discontinua-
tion (B2) and little evidence of pseudo-
podia formation but in only less than
25% of the holes. In the GHD-2 group,
all eight samples demonstrated platelet
activation. In seven of them, the grid
demonstrated the signs seen in C1 and
C2 in 70% of the holes. Furthermore, in
five of the eight samples, signs of
marked platelet aggregation were dem-
onstrated by the photographs (C3),
which corresponded to more than 85%
of the holes.
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adulthood to determine whether they represent potential in-
creased cardiovascular and thromboembolic risk in advances
stages of the deficiency.
Increased sympathetic nervous system activity has also been
associated with GHD patients (8, 9). GHD in adulthood is
commonly associated with several abnormal conditions that
could influence and suggest a sympathetic nerve activity aug-
mentation, such as excessive adiposity, insulin resistance, dys-
lipoproteinemia, increased prevalence of hypertension, arterial
function and structure worsening (increase in intima-media
thickness, atherosclerotic plaque development, and endothelial
dysfunction), and cardiovascular morbidity/mortality usually
seen in GHD patients (1, 3, 12). Two studies previously per-
formed by other groups (8, 9) demonstrated an increased mus-
cle sympathetic nerve activity in GHD adults.Whereas the first
group has suggested a high correlation between muscle sym-
pathetic nerve activity and increased DBP, the second demon-
strated an increased peripheral vascular resistance that might
beaffectedby the central sympatheticvasoconstrictordischarge
to the peripheral vasculature, which results in a pronounced
increased vasoconstriction. In our study, using plasma cate-
cholamine concentration as indirect peripheral index for the
sympathetic nervous system activity, the main finding was an
increased adrenaline content in the GHD-2 group, compared
with the (GHD-1) group, which is in agreement with a central
sympathetic vasoconstrictor discharge to the peripheral vascu-
lature, as suggestedby the other two studies (8, 9),mainly in the
groupwithmaintainedGHD. Even though the nonexistence of
differences between theGHDgroups and thematched controls,
which could be due to the age of the subjects of ourGHDgroup
(all COGHD patients after the growth completion age), de-
serves further attention, our results do not deny that sympa-
thetic hyperactivationmight also have an important role on the
vascular disease development in GHD patients, namely in ad-
vanced stages of the disturbance, as seems to be the case in the
two other above-mentioned studies (8, 9) with adult GHD
patients.
The platelet role in the physiology and pathophysiology of
the cardiovascular system, their easier collection from humans,
and the features they sharewithVSMCsmake themuseful tools
to evaluate hypothetic vascular disturbances. Accordingly,
platelets might be hypothetically implicated or might be a use-
fulmarker of cardiovascular risk in GHDpatients. Because few
studies have addressed the effects of GH, and particularly of
GHD, on platelet activation, no elucidating comparisons could
be made from our results. A previous study (48) testing the
effect of GH-releasing mechanism on platelet function demon-
strated an impairment of platelet aggregation in healthy male
volunteers infused with GH release-inhibiting hormone. The
authors suggested that the intracellularmechanisms associated
with hormonal release of the pituitary and gut endocrine cells
might resemble some metabolic mechanisms within platelets.
In our study, directly testing GHD effect on platelet function
showed no significant differences in the platelet activity pa-
rameters evaluated between the GHD-1 and control groups.
This factmight bedue to the recoveryofGH levels after therapy
withdrawal. However, patientswithmaintainedGHD (GHD-2
group) had increased thrombin-evoked [Ca2]i, collagen, and
ADP-induced platelet aggregation vs. the matched control
group, reinforced by the platelet morphology features revealed
by the electron microscopy evaluation, which seemed to indi-
cate a platelet hyperreactivity state and a putative increased
cardiovascular risk, which might be related to GHD mainte-
nance after therapy withdrawal.
GHD patients entering our study were previously sub-
mitted in most cases to other HRTs. The effect of HRT on the
cardiovascular risk, particularly in women, is a widely in-
vestigated issue, its benefits or deleterious actions remaining
controversial (49, 50). Less studied, but also unresolved, is
the hypothetic influence of HRT on hemostatic and throm-
bosis parameters (51, 52). Even considering that in our study
all the patients were already normal for all the other hor-
mones except for GH and that HRT stopped for at least 2 yr
before entry into the study, the potential influence on platelet
aggregability could not be excluded at this point and de-
serves further investigation.
Conclusions
Our study demonstrates a platelet hyperactivation state,
even in the absence of clear-cut abnormalities of the classic
vascular risk factors, including blood pressures, adiposity, or
sympathetic activity, in the GHD group of patients who do not
recover GH levels after GH therapy but not in the patients who
recovered GH levels. Minor changes in the cardiovascular risk
indexes, increased aggregation, thrombin-evoked [Ca2]i, and
morphological characteristics of platelet activation, which
might be further confirmed in adulthood,were observed in that
group, whichmight be related to GHDmaintenance after ther-
apywithdrawal. So plateletsmight represent an important tool
as earlier marker/predictor of future cardiovascular risk in the
COGHD patients and might be viewed as a predisposing con-
dition to premature vascular disease. The results suggest fur-
ther studies to better evaluate whether earlier preventive an-
tiaggregation therapy with low-dosage acetyl-salicylic acid or
clopidogrel is recommended for those patients. This prospec-
tive study also recommends supplementary confirmation and
investigation of the cellular andmolecular mechanisms under-
lying these earlier cardiovascular biochemical disturbances and
assessnot onlywhether earlierpreventive antiaggregation ther-
apy is recommended for those patients but also whether GH
replacement therapy after growth completion, although expen-
sive, is scientifically recommended to prevent cardiovascular
risk.
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